Literature DB >> 32362868

Long-Term Neurological Threats of COVID-19: A Call to Update the Thinking About the Outcomes of the Coronavirus Pandemic.

Antonio Pereira1.   

Abstract

Entities:  

Keywords:  COVID-19; SARS-CoV; coronavirus (CoV); neurotropism; synucleinopathy

Year:  2020        PMID: 32362868      PMCID: PMC7182030          DOI: 10.3389/fneur.2020.00308

Source DB:  PubMed          Journal:  Front Neurol        ISSN: 1664-2295            Impact factor:   4.003


× No keyword cloud information.
Since 11 March 2020, The World Health Organization has characterized coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 (1) as a pandemic. The outbreak started in the city of Wuhan in China and quickly spread worldwide. Coronaviruses have previously caused two large-scale pandemics in the past two decades, SARS (2) and Middle East respiratory syndrome (MERS) (3). SARS-CoV-2 is closely related to other CoV found in zoonotic reservoirs, such as bats, camels, and pangolins (4). Since SARS-CoV-2 is considerably more infectious than both SARS-CoV and MERS-CoV, many countries have determined a strict policy of “shelter-in-place” to contain the virus spread through social contagion. However, many questions remain regarding the clinical outcomes of human infection by SARS-CoV-2, including the possibility of the development of neurological disorders (5). Some viruses possess a tropism for neural tissue and are thus classified as neurotropic (e.g., herpes simplex virus type 1, rabies virus). Those viruses enter the brain through various routes, including retrograde axonal transport along axons, hematogenous spread via the blood-brain barrier (BBB), blood-cerebrospinal fluid barrier, meningeal-cerebrospinal fluid barrier, via direct infection of endothelial cells or through spreading of infected leukocytes to the brain across the BBB (6). Once in the brain, these viruses disrupt the complex organization of neural circuits either directly by neuronal damage or indirectly through host immune response pathways, causing immediate, or delayed neuropathology and neurological manifestations (6) (see below). In the short-term, neurotropic viral infections can cause inflammation of the brain parenchyma and lead to encephalitis or brain-targeted auto-immune responses in susceptible individuals (7). Possible long-term effects on hosts can include alterations on emotional and cognitive behavior, as shown in experimental animals through persistent alterations in the expression of genes involved in the regulation of synaptic activities in key brain areas (8). The axonal transport of neurotropic viruses can also turn intrinsically disordered proteins, such as α-synuclein (α-syn), into promiscuous binders that can form toxic aggregates and travel along neuronal pathways and cause cell death in areas of the brain (9). While the most common symptoms of COVID-19 at the onset of illness include fever, fatigue, dry cough, myalgia, and dyspnea, other less common symptoms are headache, abdominal pain, diarrhea, nausea, and vomiting (10). Furthermore, it's been recently reported that most patients also complain of impairment of both olfactory and gustatory perception (11) and those are being considered early markers of COVID-19 infection. Though there is longstanding evidence that human coronaviruses, such as SARS-CoV-2, can spread to the brain from the respiratory tract (5, 12, 13), the occurrence of gastrointestinal symptoms (14) suggests that the gastrointestinal system is a possible route of invasion and transmission to the enteric nervous system (ENS) (see Figure 1). While the effects of COVID-2019 on olfactory and gustatory perception may be transient, the possibility that viruses and other contaminant agents can be the initiating etiology of neurodegenerative diseases such as Parkinson's disease (PD) has been raised before (16).
Figure 1

SARS-CoV-2 invades the body through the nasal and oral cavities and may be transmitted to the brain via the olfactory bulb and the enteric nervous system (ENS). In the brain, the virus can cause neuroinflammation by microglial activation and also synucleinopathy that can be transmitted prion-like to other brain regions via the vagus nerve [adapted from Fonseca et al. (15)], from Servier Medical Art, licensed under a Creative Common Attribution 3.0 Generic License (https://www.smart.servier.com/), and Patrick J. Lynch, licensed under a Creative Common Attribution 2.5 License (https://commons.wikimedia.org/wiki/File:Head_olfactory_nerve_-_olfactory_bulb_en.png).

SARS-CoV-2 invades the body through the nasal and oral cavities and may be transmitted to the brain via the olfactory bulb and the enteric nervous system (ENS). In the brain, the virus can cause neuroinflammation by microglial activation and also synucleinopathy that can be transmitted prion-like to other brain regions via the vagus nerve [adapted from Fonseca et al. (15)], from Servier Medical Art, licensed under a Creative Common Attribution 3.0 Generic License (https://www.smart.servier.com/), and Patrick J. Lynch, licensed under a Creative Common Attribution 2.5 License (https://commons.wikimedia.org/wiki/File:Head_olfactory_nerve_-_olfactory_bulb_en.png). Parkinson's disease (PD) is a common neurodegenerative disorder associated with the progressive loss of dopaminergic neurons located in the midbrain nucleus substantia nigra pars compacta (SNpc) due to the accumulation of α-synuclein (α-syn) aggregates. The Braak hypothesis (9) for the etiology of sporadic Parkinson's disease (PD) proposes that a neurotropic virus invading neural tissue through the nasal cavity and the gastrointestinal tract causes α-syn to turn into a promiscuous binder and be transmitted, prion-like, to key areas such as the SNpc (15). Interestingly, the prodromal or preclinical phase of PD is also characterized by olfactory and gastrointestinal symptoms (17). The cellular receptor for SARS-CoV-2 is the angiotensin-converting enzyme 2 (ACE2), which has a role in the metabolism of angiotensin peptides involved in the control of vasoconstriction and blood pressure (18). ACE2 is found in several tissues associated with cardiovascular function, but also in the brain, including brainstem nuclei involved with cardio-respiratory regulation (19, 20). Thus, respiratory problems in COVID-19 patients could also derive from the direct action of SARS-CoV-2 in respiratory control nuclei in the Brain (21). Through its binding to ACE2 receptors, SARS-CoV-2 may spread transneuronally to distant brain targets, similar to other neurotropic viruses (22), as predicted by the Braak hypothesis. Thus, recovery may be an ambiguous term regarding COVID-19. Though recovery from the acute phase of the infections is certainly a relief in public health terms, helping to stop the spreading of the infection, one must consider the long-term neurological effects of the disease. This discussion has been conspicuously lacking in pertinent forums and needs to be adequately addressed as an important concern by public health officials. Many authorities are focusing only on the risks posed to the elderly and immunocompromised subjects, downplaying the threats to younger populations. Though the neurological risks described in the present work are particularly important to the elderly, due to age-related degenerative processes in the immunologic system and the brain, the population needs to be alerted to the chronic neurological risks during the pandemic and maintain social distancing for as long as it is necessary.

Author Contributions

AP conceived and wrote the manuscript.

Conflict of Interest

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
  21 in total

Review 1.  Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen.

Authors:  H Braak; U Rüb; W P Gai; K Del Tredici
Journal:  J Neural Transm (Vienna)       Date:  2003-05       Impact factor: 3.575

2.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

3.  Influenza A virus infection causes alterations in expression of synaptic regulatory genes combined with changes in cognitive and emotional behaviors in mice.

Authors:  S Beraki; F Aronsson; H Karlsson; S O Ogren; K Kristensson
Journal:  Mol Psychiatry       Date:  2005-03       Impact factor: 15.992

4.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.

Authors:  Ali M Zaki; Sander van Boheemen; Theo M Bestebroer; Albert D M E Osterhaus; Ron A M Fouchier
Journal:  N Engl J Med       Date:  2012-10-17       Impact factor: 91.245

Review 5.  Viral-induced suppression of self-reactive T cells: Lessons from neurotropic coronavirus-induced demyelination.

Authors:  Carine Savarin; Cornelia C Bergmann
Journal:  J Neuroimmunol       Date:  2017-01-11       Impact factor: 3.478

Review 6.  Neurologic Alterations Due to Respiratory Virus Infections.

Authors:  Karen Bohmwald; Nicolás M S Gálvez; Mariana Ríos; Alexis M Kalergis
Journal:  Front Cell Neurosci       Date:  2018-10-26       Impact factor: 5.505

7.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

8.  COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission.

Authors:  Jinyang Gu; Bing Han; Jian Wang
Journal:  Gastroenterology       Date:  2020-03-03       Impact factor: 22.682

9.  Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak.

Authors:  Tao Zhang; Qunfu Wu; Zhigang Zhang
Journal:  Curr Biol       Date:  2020-03-19       Impact factor: 10.834

Review 10.  Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System?

Authors:  Marc Desforges; Alain Le Coupanec; Philippe Dubeau; Andréanne Bourgouin; Louise Lajoie; Mathieu Dubé; Pierre J Talbot
Journal:  Viruses       Date:  2019-12-20       Impact factor: 5.048

View more
  12 in total

Review 1.  COVID-19 Neurological Manifestations and Underlying Mechanisms: A Scoping Review.

Authors:  Angela Wenting; Angélique Gruters; Yindee van Os; Sonja Verstraeten; Susanne Valentijn; Rudolf Ponds; Marjolein de Vugt
Journal:  Front Psychiatry       Date:  2020-08-21       Impact factor: 4.157

2.  Psycho-Neuroendocrine-Immune Interactions in COVID-19: Potential Impacts on Mental Health.

Authors:  Ícaro Raony; Camila Saggioro de Figueiredo; Pablo Pandolfo; Elizabeth Giestal-de-Araujo; Priscilla Oliveira-Silva Bomfim; Wilson Savino
Journal:  Front Immunol       Date:  2020-05-27       Impact factor: 7.561

Review 3.  Cognitive impact of COVID-19: looking beyond the short term.

Authors:  Scott Miners; Patrick G Kehoe; Seth Love
Journal:  Alzheimers Res Ther       Date:  2020-12-30       Impact factor: 6.982

4.  Neuroinvasion of SARS-CoV-2 in human and mouse brain.

Authors:  Eric Song; Ce Zhang; Benjamin Israelow; Alice Lu-Culligan; Alba Vieites Prado; Sophie Skriabine; Peiwen Lu; Orr-El Weizman; Feimei Liu; Yile Dai; Klara Szigeti-Buck; Yuki Yasumoto; Guilin Wang; Christopher Castaldi; Jaime Heltke; Evelyn Ng; John Wheeler; Mia Madel Alfajaro; Etienne Levavasseur; Benjamin Fontes; Neal G Ravindra; David Van Dijk; Shrikant Mane; Murat Gunel; Aaron Ring; Syed A Jaffar Kazmi; Kai Zhang; Craig B Wilen; Tamas L Horvath; Isabelle Plu; Stephane Haik; Jean-Leon Thomas; Angeliki Louvi; Shelli F Farhadian; Anita Huttner; Danielle Seilhean; Nicolas Renier; Kaya Bilguvar; Akiko Iwasaki
Journal:  J Exp Med       Date:  2021-03-01       Impact factor: 17.579

Review 5.  COVID-19 and Alzheimer's Disease.

Authors:  Marcello Ciaccio; Bruna Lo Sasso; Concetta Scazzone; Caterina Maria Gambino; Anna Maria Ciaccio; Giulia Bivona; Tommaso Piccoli; Rosaria Vincenza Giglio; Luisa Agnello
Journal:  Brain Sci       Date:  2021-02-27

Review 6.  Biomaterial-based immunoengineering to fight COVID-19 and infectious diseases.

Authors:  Jana Zarubova; Xuexiang Zhang; Tyler Hoffman; Mohammad Mahdi Hasani-Sadrabadi; Song Li
Journal:  Matter       Date:  2021-03-09

7.  Speech-Language Pathologists' Role in the Multi-Disciplinary Management and Rehabilitation of Patients with Covid-19.

Authors:  Bijoyaa Mohapatra; Ranjini Mohan
Journal:  J Rehabil Med Clin Commun       Date:  2020-07-27

8.  Persistent Retinal Microvascular Impairment in COVID-19 Bilateral Pneumonia at 6-Months Follow-Up Assessed by Optical Coherence Tomography Angiography.

Authors:  Valentina Bilbao-Malavé; Jorge González-Zamora; Manuel Saenz de Viteri; Miriam de la Puente; Elsa Gándara; Anna Casablanca-Piñera; Claudia Boquera-Ventosa; Javier Zarranz-Ventura; Manuel F Landecho; Alfredo García-Layana
Journal:  Biomedicines       Date:  2021-05-02

Review 9.  Impact of SARS-CoV-2 on neuropsychiatric disorders.

Authors:  Maria Angeles Robinson-Agramonte; Carlos-Alberto Gonçalves; Elena Noris-García; Naybí Préndes Rivero; Anna Lisa Brigida; Stephen Schultz; Dario Siniscalco; Ramiro Jorge García García
Journal:  World J Psychiatry       Date:  2021-07-19

Review 10.  The Impact of the COVID-19 Pandemic on Dementia Risk: Potential Pathways to Cognitive Decline.

Authors:  Jeffrey D Pyne; Adam M Brickman
Journal:  Neurodegener Dis       Date:  2021-07-28       Impact factor: 2.977

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.